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Lung cancer is responsible for more than one million deathsper annum worldwide and is the leading cause of cancer
mortality.1 Most patients with lung cancer are not cured, and
the overall 5-year survival rate is approximately 15%. The
combination of cisplatin or carboplatin with third-generation
agents, such as gemcitabine, paclitaxel, docetaxel, or vinorel-
bine, represents the standard of care for fit patients with
advanced non-small cell lung cancer (NSCLC),2 whereas
single-agent therapy with vinorelbine or gemcitabine repre-
sents the standard approach for unfit or elderly patients with
NSCLC.3 Recent advances in the knowledge of cancer biol-
ogy have led to the identification of several potential molec-
ular targets that play a key role in cancer development and
progression.
The epidermal growth factor receptors (EGFRs) stand
at the origin of a major signaling pathway involved in the
growth of lung cancer. The EGFR superfamily includes four
distinct, closely related transmembrane receptors: EGFR/
erbB-1, HER2/erbB-2, HER3/erbB-3, and HER4/erbB-4.4
EGFR is normally found on the surface of epithelial cells and
is often overexpressed in a variety of human malignancies.
Several compounds have been developed against EGFR, with
tyrosine-kinase inhibitors (TKIs) being the most widely in-
vestigated agents. In this review, we focus on molecular
predictors for sensitivity and resistance to EGFR-TKIs.
EGFR-TKIS
Several compounds have been developed to reversibly
or irreversibly bind EGFR. Gefitinib (ZD 1839; Iressa, As-
traZeneca, London, UK) and erlotinib (OSI 774; Tarceva,
Genentech, South San Francisco, CA) are the first EGFR-
TKIs that have reached clinical trial testing.
Large phase II trials showed that gefitinib and erlotinib
were active in pretreated NSCLC,5–7 but the promising
EGFR-TKI single-agent activity observed in these studies has
been unattended in subsequent phase III combination trials.
Four large prospective studies, including more than 4000
patients with advanced NSCLC, randomly assigned untreated
patients to standard chemotherapy plus a TKI, or the same
chemotherapy regimen plus placebo.8–11 All trials failed to
demonstrate any survival advantage for patients receiving the
TKI, probably because of the lack of patient selection.
Two large, randomized, phase III studies have recently
assessed gefitinib and erlotinib as single agents for the treat-
ment of patients with advanced NSCLC who failed at least
one chemotherapy regimen.12,13 The ISEL trial failed to
demonstrate a survival advantage for gefitinib over best
supportive care in advanced NSCLC (5.6 vs 5.1 months; p 
0.09), whereas the BR21 trial, in which 731 previously
treated patients with advanced NSCLC were randomized to
receive erlotinib 150 mg/day or placebo, succeeded in meet-
ing its primary endpoint, with patients in the experimental
arm experiencing a statistically significant improvement in
overall survival with a hazard ratio of 0.70.13
PREDICTIVE FACTORS TO ANTI-EGFR AGENTS
Several clinical and biological features significantly
associate with EGFR-TKI sensitivity, with some factors be-
ing predictive only for response and others also for survival.
Retrospective analyses of large phase II and III trials with
TKIs showed that never-smoking history5–7 was the most
relevant clinical feature associated with TKIs sensitivity,
either in terms of response or survival,8–14 suggesting that
TKIs could represent a valid alternative to standard chemo-
therapy in never-smokers with NSCLC.
EGFR expression assessed by immunohistochemistry
(IHC) is the first biological marker to be retrospectively
explored in cohorts of patients with NSCLC treated with
TKIs. The vast majority of studies found no association
between EGFR protein expression and patient outcome.15–18
Conversely, we observed a higher response rate and longer
survival in EGFR IHC-positive patients treated with gefitinib
versus EGFR IHC-negative patients.19 In the ISEL and BR21
trials, EGFR-expressing patients treated with TKIs had better
survival than EGFR IHC-positive individuals treated with
placebo, although the interaction did not reach statistical
significance in the latter study.20,21
EGFR somatic mutations initially found in small co-
horts of TKI-responding patients were widely explored in
patients with NSCLC exposed to these agents.19,22,23 The vast
majority of studies showed a significant association between
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EGFR mutations, especially exon 19 deletion, and response
to TKIs,24 and recent prospective studies have confirmed that
gefitinib or erlotinib responders harbored an EGFR gene
mutation.25,26
Although available data indicate that patients with
EGFR mutations respond to TKIs, the impact on survival is
unclear because of the possible prognostic, rather than
predictive, value of such mutations, and the possible dif-
ferent role of exon 19 rather than exon 21 mutation in TKI
sensitivity.20,27–33 Prospective trials are needed to further
define the prognostic and predictive roles of different
EGFR mutations.
Several studies19–21,34 evaluated EGFR gene copy num-
ber by fluorescence in situ hybridization (FISH) as a possible
predictor for sensitivity to TKIs. In the BR21 and ISEL trials,
EGFR FISH-positive patients treated with a TKI had higher
response rate and longer survival than EGFR FISH-positive
patients treated with placebo, whereas there was no advan-
tage determined by the drug in FISH-negative patients.20,21 It
is noteworthy that a recently completed prospective trial has
confirmed the relevance of EGFR gene gain assessed by
FISH in predicting sensitivity to TKIs.35
In summary, although prospective studies are needed,
the available data suggest that EGFR FISH analysis is an
accurate predictor for gefitinib sensitivity and that this method
should be used for the selection of patients for candidates for
TKI therapy. Other methods for EGFR gene copy number
assessment produced conflicting results and are not recom-
mended outside clinical trials.
MECHANISMS OF TKI RESISTANCE
Resistance to TKIs could be the result of biological
factors present before drug exposure (primary resistance) or
could develop after an initial response (acquired resistance).
The main mechanisms associated with intrinsic EGFR-TKI
resistance are the presence of k-ras mutation or HER2 muta-
tion.29,35 K-ras is a critical downstream effector of the EGFR
pathway that has been found to be mutated in approximately
15% to 30% of lung adenocarcinomas and to be associated
with tobacco smoke exposure.36,37 Pao et al. have investi-
gated the possible role of k-ras mutations in 60 patients with
lung adenocarcinomas sensitive or refractory to either ge-
fitinib or erlotinib.38 K-ras mutations were identified in 24%
of patients refractory to either drug, whereas no mutations
were found in the 21 sensitive patients. In the BR21 study,
patients with the k-ras mutation had a lower response rate
and significantly shorter survival than those with wild-type
k-ras.39 These data indicated that k-ras mutations are associ-
ated with intrinsic TKI resistance, and k-ras gene sequencing
could be useful for the selection of patients as candidates for
TKI therapy.
Mutation of the HER2 gene was reported in lung
adenocarcinoma, offering the potential for additional therapy
targeted to the altered protein.40 HER2 mutations, which
mainly consist of exon 20 insertions/duplications, target the
same corresponding region as EGFR mutations.40,41 These
mutations were more frequently observed in never-smok-
ers and in adenocarcinomas,40,41 and recent findings have
indicated that NSCLCs presenting these mutations remain
sensitive to HER2-targeted therapies but insensitive to
EGFR-TKIs.42,43
Despite an initial response to EGFR-TKIs, all patients
invariably progress and die of their disease. The main mech-
anism associated with acquired TKI resistance is an EGFR
T790M mutation that has been reported in approximately half
of patient tumors after disease progression.44,45
Understanding the basis for acquired EGFR-TKI resis-
tance has led to the identification of agents that may over-
come acquired resistance. Preclinical studies showed that
irreversible EGFR-TKIs46 may have activity in patients with
acquired resistance to either gefitinib or erlotinib. Prospective
studies are currently ongoing and will clarify the role of these
agents in EGFR-TKI–resistant patients.
CONCLUSIONS
Anti-EGFR strategies have been widely investigated in
the last years. Among them, EGFR-TKIs have emerged as
highly effective agents in subsets of patients with lung can-
cer. Never-smoking status emerged as the most relevant
clinical predictor for TKI activity, whereas increased EGFR
gene copy number assessed by FISH and the presence of
EGFR-activating mutations represent critical biological fac-
tors for proper patient selection. Moreover, growing interest
is emerging around molecular predictors for resistance to
these agents. However, most available data derive from
retrospective analyses; therefore, prospective validation is
needed. Currently ongoing phase II and III trials will hope-
fully allow the identification of the optimal paradigm for
patient selection.
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